News
Moving ahead: Copan announces a major rebranding and launches a new website
Time of change for Copan. The Italian preanalytics company announced the completion of an extensive rebranding initiative which includes a new logo and a new website with updated functionalities. The rebranding aims to represent at best the company values and offer an improved customer experience.
News
U.S.I.T.C. Institutes Unfair Competition Investigation of Imported Flocked Swabs and Kits
On Friday, August 27, 2021, the United States International Trade Commission instituted an unfair importation investigation against several manufacturers and distributors of imported flocked swabs and products containing the flocked swabs and infringing several of our US-issued patents.
News
COPAN Resolves U.S.I.T.C. Unfair Competition Investigation with Several Manufacturers and Distributors of Imported Flocked Swabs
Copan announces the resolution of its United States International Trade Commission complaint with many companies involved, filing a joint request with each settling respondent seeking termination from the ongoing investigation as a result of the settlements.
News
ECCMID 2022: Copan unveils its WISE approach to sample management
Copan took the chance of the first in-person ECCMID of the last two years to give a name to its holistic approach to preanalytics. From sample collection to image analysis and data interpretation, meet Copan’s WISE approach, which brings any sample to improved diagnostics.
News
Copan Group: from the efforts against the pandemic to the investments for a sustainable development
Despite the unpredictable scenario caused by the pandemic, 2021 was another positive year for Copan. Behind a turnover of 395 million euros, the company has adopted a global industrial strategy and investments aimed at sustainable development. Following these principles, the Group is preparing to face the challenges of the post-pandemic market.
News
Copan FecalSwab® receives the 510(k) FDA clearance for molecular use with the BD MAX™ Enteric & Extended Enteric Bacterial Panels
Copan announces the 510(k) FDA clearance of its Copan FecalSwab® for collecting and transporting stool samples to be processed with BD Enteric Bacterial Panel and BD Extended Enteric Bacterial Panel on the BD MAX™ System. This clearance opens new molecular diagnostic opportunities for customers who already use FecalSwab® to maintain enteric pathogens’ vitality for microbial culturing.
News
Copan Announces Leadership Change
Copan Group has announced significant leadership changes at its Japanese subsidiary, Copan Japan. After five years of dedicated service, Mr. Shinji Matsuura has stepped down as CEO of the Company he co-founded with Stefania Triva in 2018. Effective October 31st, 2023, Mr. Nicola Arrighi has assumed the CEO role.
Video
Copan’s global response to COVID-19
To react to the extraordinary demand for our SARS-CoV-2 collection kits caused by the current pandemic, at Copan we have rethought our approach to every side of our activity. Although the emergency is still far from being over, we are committed to facing it with the motivation that has always distinguished us.
Video
From the pandemic and beyond
During 2020 we faced the pandemic head-on, boosting our COVID-related production capacity and bringing our manufacturing sites closer to the end-markets. But how we did that? Of course, putting the safety and welfare of our employees first.
Copan’s international family has grown and is ready to face what the future will bring!
